Medigene AG Highlights Groundbreaking Potential of TCR-T Therapy at International Conferences

The biotechnological company Medigene AG assumes a leading role in immuno-oncological research with a focus on solid tumor forms and presented significant results of their TCR-T cell development at the Annual Meeting of the American Association for Cancer Research (AACR) 2024. The display of the poster with pioneering research findings on the safety and functionality of TCR-T cells with an integrated costimulatory switch protein is a striking evidence of the company's innovation potential in the fight against cancer. The poster, entitled 'TCR-gated control of costimulatory switch protein (CSP) activation in rTCR-T cells expressing PD1-41BB', was compiled by a competent team of researchers and demonstrated that rTCR-T cells fortified with PD1-41BB CSP show improved performance and safety. The poster thereby indicates a significant advancement in combating advanced cancer diseases and was presented on April 7th. Interested parties can access the abstract online, while the poster will be made available subsequently. Medigene's innovative approach will also be applied in an initial clinical study for MDG1015, a TCR-T therapy based on the principle of the costimulatory switch protein, targeting various cancers such as stomach cancer or sarcomas, with plans to submit the IND/CTA application in the second half of 2024. Furthermore, Medigene had the opportunity to speak at the ELRIG Forum 2024 in Darmstadt. Dr. Barbara Lösch, as Head of Technology & Innovation at the company, discussed the complexity of the company's proprietary technology and innovation platform in her lecture 'Evolution by Innovation: Connecting the Dots of TCR-T Therapies'. The lecture provided comprehensive insight into various platform technologies intended to drive the development of high-ranking TCR-T therapies. The presentation will also be made available online via the company's website. In light of these achievements, Medigene presents itself as a living example of innovative spirit and therapeutic progress in immuno-oncology, with an extensive range of proprietary technologies and collaborations, including partnerships with industry leaders such as BioNTech and 2seventy bio.